HomeAI · summaries
Storia in 14 fonti
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies
GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential finite treatment course, a significant advancement over lifelong antiviral pills for the over 250 million people globally living with chronic hepatitis B.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’
The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.
- ·
apnews.com
Experimental hepatitis B drug may offer 'functional cure' for some patients
New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus.
